UBX Profile
Unity Biotechnology, Inc. is a pioneering biotechnology firm dedicated to developing therapeutics aimed at addressing diseases associated with aging. The company focuses on creating innovative treatments designed to slow, halt, or potentially reverse the effects of age-related conditions. Unity's research is centered on targeting cellular senescence, a key driver of various age-related diseases, through its proprietary technology platforms.
Unity's lead therapeutic candidate is UBX1325, which is currently undergoing Phase II clinical trials. This investigational drug is designed to treat age-related ocular diseases such as diabetic macular edema, age-related macular degeneration (AMD), and diabetic retinopathy. UBX1325 represents a significant advancement in addressing these debilitating conditions, offering the potential for improved outcomes for patients suffering from severe vision impairment due to age-related factors.
In addition to UBX1325, Unity is developing several other promising drug candidates. UBX1967 is being explored for its potential in treating various ophthalmologic diseases, further expanding the company's portfolio in eye care. UBX2050 is a human anti-Tie2 agonist monoclonal antibody targeted at age-related eye diseases, while UBX2089, a Klotho hormone drug candidate, is under investigation for multiple neurological indications. These programs reflect Unity's commitment to leveraging advanced scientific approaches to tackle complex age-related health issues.
Originally known as Forge, Inc., the company rebranded to Unity Biotechnology, Inc. in January 2015, following its incorporation in 2009. Headquartered in South San Francisco, California, Unity continues to advance its research and development efforts, driven by a mission to transform the treatment of age-related diseases and improve the quality of life for aging populations. The company's innovative approach and robust pipeline underscore its role as a leader in the field of geroscience and therapeutic development.
|
